Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-strategy randomized trial for treatment of antiretroviral-naive HIV and tuberculosis coinfected adults
PACTR201105000291300Recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Randomised, open-label trial of rifampicin in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (3 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Mortality from all causes. Started May 2011; status: recruiting.
02
Drugs
rifampicin
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201105000291300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201105000291300.